The use of T cell receptors (TCRs) as potential therapeutic agents provides an opportunity to
target a greatly expanded array of antigens, compared to those now targeted with
monoclonal antibodies. With the advent of new display technologies and TCR formats for in
vitro engineering, it should be possible to generate high-affinity TCRs against virtually any
peptide antigen that is shown to bind to a major histocompatibility complex (MHC) molecule
(eg peptides derived from viral antigens or from self proteins that are associated with the …